4779 |
Immediate Clinical Outcomes, Hemodynamic Performance, and Leaflet Thrombosis Following Transcatheter Aortic Valve Replacement With the Latest Intra-Annular Devices |
Juri Iwata |
Apr. 19. 24 |
4778 |
The Association Between Free Fatty Acid and Adverse Outcomes in Patients Undergoing Percutaneous Coronary Intervention With or Without Diabetes Mellitus: A Single-Center Cohort Study. |
Qinxue Li |
Apr. 19. 24 |
4777 |
VARIANT-ICD Trial: ICD vs. Medical Therapy Alone in Variant Angina With Aborted SCD |
Jung-Min Ahn |
Apr. 19. 24 |
4776 |
ASSURE-DES Trial: Optimal Antiplatelet Strategy in DES Patients During Noncardiac Surgery |
Hanbit Park |
Apr. 19. 24 |
4775 |
PROTECT-HBR Trial: New GI Protection Drug for High-Bleeding Risk Patients Requiring Antithrombotic Agents - P-CAB vs. PPI |
Jinho Lee |
Apr. 19. 24 |
4774 |
EPIC-CAD Trial: Long-Term Antithrombotic Strategy in AF Patients With Stable CAD |
Gi-Byoung Nam |
Apr. 19. 24 |
4773 |
FATE-MAIN Trial: FFR- vs. Angiography-guided Left Main PCI |
Jung-Min Ahn |
Apr. 19. 24 |
4772 |
DEFINE-DM Trial: Imaging- and Physiology-guided State-of-the Art PCI vs. CABG for DM and Multi-Vessel Disease |
Hoyun Kim |
Apr. 19. 24 |
4771 |
ENAVO-TAVR Trial: SGLT-2 Inhibitor for Post-TAVR |
Jinho Lee |
Apr. 19. 24 |
4770 |
TAILORED-CHIP Trial: Temporal Dynamic Antiplatelet Strategy for Complex High-Risk PCI |
Hanbit Park |
Apr. 19. 24 |